REMS Templates Get Nod From FDA, With Nudge From Pharmacists
This article was originally published in The Pink Sheet Daily
Executive Summary
At workshop, agency acknowledges efficiency and implementation burdens that the myriad risk management program programs create, but developing a standardized approach will not easy task either.
You may also be interested in...
“Adaptive Licensing” Proposals View REMS As Answer To Limited Evidence
Some ideas for new drug approval pathways seem to envision the use of Risk Evaluation and Mitigation Strategies as a means for preventing and monitoring off-label use following initial approval, apparently without regard to the seriousness or extent of a product’s risks. Given the burdens currently created by REMS, any effort to expand and retrofit the programs to a new approval pathway is likely to draw pushback from the health care community.
PDUFA Commitment Letter Formalizes REMS Standardization Schedule
Among other timetables set as part of the broad deal with industry, FDA will host meetings and issue guidances to assess and minimize the burden of REMS on the practitioners and patients.
PDUFA Commitment Letter Formalizes REMS Standardization Schedule
Among other timetables set as part of the broad deal with industry, FDA will host meetings and issue guidances to assess and minimize the burden of REMS on the practitioners and patients.